Cancer literatures proved that miR-22-3p targets SP1, inhibits the expression of downstream genes CCND1 and BCL2, thereby inhibiting the growth of liver cancer cells, and the low expression of miR-22-3p is associated with metastatic liver cancer [27,28]. Here, BCL2 is linked to cancer.